Phase 4
Completed N=106
PPIs and Gastroesophageal Varices in Liver Cirrhosis (PPIs: Proton Pump Inhibitors)
Cirrhosis · Hypertension, Portal
Source: ClinicalTrials.gov NCT03175731 ↗
Enrolled (actual)
106
Serious AEs
0.0%
Results posted
Jun 2021
Primary outcomePrimary: Variceal Bleeding Events — 3; 3 Participants
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
This study is aimed at investigating the effect of PPIs on gastroesophageal varices in liver cirrhosis. Half of participants will receive PPI, while the other half will receive a placebo.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Variceal Bleeding Events |
3; 3 | — |
| SECONDARY Mortality |
1; 0 | — |
| SECONDARY Adverse Eventsafter Endoscopic Therapy |
15; 20 | — |
Eligibility Criteria
Inclusion Criteria
- Clinical diagnosis of cirrhosis
- GEVs was diagnosed by endoscopy
Exclusion Criteria
- Acute gastrointestinal bleeding need emergency surgery
- Acid-related disease, such as peptic ulcer disease or gastroesophageal reflux diseases (GERD)
- Hepatocellular carcinoma (HCC) or other malignant tumor
- History of esophagus, stomach or liver surgery
- Child-Pugh C and can't be improved to Child-Pugh A or B
- Preparing to be pregnant, pregnant or breast feeding
- Allergic to PPIs(proton pump inhibitors) or intolerable
- Cannot provide informed consent
Data sourced from ClinicalTrials.gov (NCT03175731). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.